- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06840886
Een studie van PHST001 in geavanceerde solide tumoren
Een open-label, fase 1A/1B, dosis escalatie en dosis expansiestudie onderzoek naar de veiligheid, farmacokinetiek, farmacodynamica en antitumoractiviteit van PHST001 bij volwassen patiënten met gevorderde terugvorderde en/of vuurvaste vaste tumoren
This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with anticancer therapies (Phase 1b) in adult participants with advanced relapsed and/or refractory solid tumors (including but not limited to CNS tumors in Phase 1a only). Phase 1b will include the following cohorts 1) tumor-specific cohorts for participants with advanced relapsed and/or refractory ovarian cancer, endometrial cancer, and cholangiocarcinoma, 2) a randomized cohort for participants with ovarian cancer who will receive PHST001 in combination with mirvetuximab soravtansine, 3) a cohort for participants with advanced/metastatic breast cancer who will receive PHST001 in combination with trastuzumab deruxtecan and 4) a cohort of patients who consent to additional biomarker studies.
The study's primary objectives are to evaluate the safety and tolerability of PHST001 and determine the RP2D (Recommended Phase 2 dose) of PHST001 as monotherapy and in combination with anticancer therapies, as well as to assess the anti-tumor activity of PHST001 in combination with anticancer therapies in Phase 1b.
Studie Overzicht
Toestand
Conditie
Studietype
Inschrijving (Geschat)
Fase
- Fase 1
Contacten en locaties
Studiecontact
- Naam: Raphaël Rousseau, Chief Medical Officer, PhD, MD
- Telefoonnummer: 650-260-8443
- E-mail: medical@pheast.com
Studie Locaties
-
-
California
-
Beverly Hills, California, Verenigde Staten, 90212
- Werving
- Precision NextGen Oncology & Research Center
-
Contact:
- Jing Liu
- Telefoonnummer: 424-777-0708
- E-mail: JingL@nextgenonc.com, research@nextgenonc.com
-
Hoofdonderzoeker:
- Kamlesh Kumar Sankhala, MD
-
Los Angeles, California, Verenigde Staten, 90033
- Werving
- USC Norris Comprehensive Cancer Center
-
Contact:
- Lorraine Martinez
- E-mail: Lorraine.Martinez@med.usc.edu
-
Contact:
- Stephanie Kim
- E-mail: Stephanie.Kim2@med.usc.edu
-
Palo Alto, California, Verenigde Staten, 94304
- Werving
- Stanford University School of Medicine
-
Contact:
- Kayla McDaniel
- Telefoonnummer: 650-498-7293
- E-mail: mcda59@stanford.edu
-
Hoofdonderzoeker:
- Oliver Dorigo, MD, PhD
-
-
Colorado
-
Denver, Colorado, Verenigde Staten, 80218
- Werving
- Sarah Cannon Research Institute (SCRI) Oncology Partners - Denver Health One
-
Contact:
- Sarah Cannon Research Institute at HCA HealthONE
- Telefoonnummer: 720-754-2610
- E-mail: CANN.DDUDenverGeneral@SarahCannon.com
-
-
Connecticut
-
New Haven, Connecticut, Verenigde Staten, 06520
- Werving
- Yale Cancer Center
-
Hoofdonderzoeker:
- Michael Cecchini, MD
-
Contact:
- Priscilla Stéve
- Telefoonnummer: 203-464-5564
- E-mail: Priscilla.steve@yale.edu
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60637
- Werving
- University of Chicago Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02215
- Werving
- Dana Farber Cancer Institute
-
Hoofdonderzoeker:
- Michael Dennis, MD
-
Contact:
- DFCI CCTI Referrals
- E-mail: dfcicctiexternalreferral@dfci.harvard.edu
-
-
Michigan
-
Ann Arbor, Michigan, Verenigde Staten, 48109
- Werving
- University of Michigan Rogel Cancer Center
-
Hoofdonderzoeker:
- Ulka Vaishampayan, MD
-
Contact:
- University of Michigan Health Cancer AnswerLine
- Telefoonnummer: 1-800-865-1125
- E-mail: canceranswerline@med.umich.edu
-
Grand Rapids, Michigan, Verenigde Staten, 49546
- Werving
- START Center for Cancer Research - Midwest
-
Hoofdonderzoeker:
- Sreenivasa Chandana, MD, PhD
-
Contact:
- START HOPE Team
- E-mail: hopeteam@startresearch.com
-
-
New York
-
Lake Success, New York, Verenigde Staten, 11042
- Werving
- START Center for Cancer Research - Long Island New York
-
Hoofdonderzoeker:
- Geraldine O'Sullivan Coyne, MD
-
Contact:
- Sadia Morium
- Telefoonnummer: 363-207-5166
- E-mail: sadia.morium@startresearch.com
-
New York, New York, Verenigde Staten, 10029
- Werving
- Mount Sinai
-
Hoofdonderzoeker:
- Thomas Marron, MD, PhD
-
Contact:
- Jordan Cuevas
- Telefoonnummer: 212-824-7945
- E-mail: jordan.cuevas@mssm.edu
-
-
North Carolina
-
Durham, North Carolina, Verenigde Staten, 27710
- Werving
- Duke Cancer Institute
-
Contact:
- Phase 1 and Immunotherapy Team
- Telefoonnummer: 919-684-6342
- E-mail: Phase1andImmunotherapyreferrals@duke.edu
-
Hoofdonderzoeker:
- Niharika Mettu, MD, PhD
-
-
Tennessee
-
Nashville, Tennessee, Verenigde Staten, 37203
- Werving
- Vanderbilt-Ingram Cancer Center
-
Contact:
- Clinical Trials Office (CTO)
- Telefoonnummer: 1-800-811-8480
- E-mail: cip@vumc.org
-
Hoofdonderzoeker:
- Elizabeth Davis, MD, PhD
-
Nashville, Tennessee, Verenigde Staten, 37203
- Werving
- Sarah Cannon Research Institute (SCRI) Oncology Partners
-
Hoofdonderzoeker:
- Deepak Bhamidipati, MD
-
Contact:
- SCRI Oncology Partners - Nashville
- Telefoonnummer: 1-877-MY-1-SCRI (691-7274)
- E-mail: ASKSARAH@scresearch.net
-
-
Texas
-
Fort Worth, Texas, Verenigde Staten, 76104
- Werving
- START Center for Cancer Research - Texas
-
Contact:
- START HOPE Team
- E-mail: hopeteam@startresearch.com
-
Hoofdonderzoeker:
- Henry Xiong, MD, PhD
-
Houston, Texas, Verenigde Staten, 77030
- Werving
- MD Anderson Cancer Center
-
Contact:
- MD Anderson Cancer Center
- Telefoonnummer: 713-563-1930
- E-mail: ICTNPCS@mdanderson.org
-
Hoofdonderzoeker:
- Stéphane Champiat, MD, PhD
-
Irving, Texas, Verenigde Staten, 75039
- Werving
- NEXT Oncology - Dallas
-
Hoofdonderzoeker:
- Michael Song, MD, PhD, PharmD
-
Contact:
- NEXT Referrals-Dallas
- Telefoonnummer: fax: 210-568-4577
- E-mail: nxt_txreferrals@nextoncology.com
-
San Antonio, Texas, Verenigde Staten, 78229
- Werving
- University of Texas (UT) Health
-
Hoofdonderzoeker:
- Daruka Mahadevan, MD, PhD
-
Contact:
- Mays Cancer Center Research Team
- E-mail: mccresearch@uthscsa.edu
-
San Antonio, Texas, Verenigde Staten, 78229
- Werving
- START Center for Cancer Research - San Antonio
-
Hoofdonderzoeker:
- Kyriakos Papadopoulos, MD
-
Contact:
- START HOPE Team
- Telefoonnummer: 210-593-5250
- E-mail: hopeteam@startresearch.com
-
-
Virginia
-
Fairfax, Virginia, Verenigde Staten, 22031
- Werving
- NEXT Oncology - Virginia
-
Contact:
- Carrie Friedman
- E-mail: adelgado@nextoncology.com
-
Contact:
- Allison Delgado
- E-mail: carrie.friedman@usoncology.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Key Inclusion Criteria:
- Histologically or cytologically confirmed advanced solid tumor which has relapsed from or been refractory to all locally available standard therapies.
- Adequate organ function per laboratory testing
- Pregnancy prevention requirements
- Measurable disease per RECIST v1.1 (or RANO) as assessed by the local site Investigator/radiology
- Performance status of 0 or 1 on Eastern Cooperative Oncology Group (ECOG) scale
Key Exclusion Criteria:
- Diagnosis of immunodeficiency
- History of a previous additional malignancy, unless potentially curative treatment has been completed, with no evidence of malignancy for 2 years. Participants with basal cell carcinoma of the skin, Stage I melanoma, melanoma in situ, squamous cell carcinoma of the skin, early-stage prostate cancer, low grade neoplasms, or carcinoma in situ, excluding carcinoma in situ of the bladder, who have undergone potentially curative therapy are not excluded and can be enrolled regardless of disease-free period following completion of potentially curative therapy. Participants with early-stage breast cancer who have undergone curative intent treatment and with no disease recurrence for 2 years after treatment are not excluded.
- Active known CNS metastases and/or carcinomatous meningitis from a systemic (non-CNS) primary malignancy. Participants with previously treated CNS metastases are eligible, provided they are radiologically and clinically stable (i.e., no evidence of progression for at least 2 weeks by repeat imaging performed during screening) and are not requiring systemic corticosteroids above the physiologic replacement for at least 7 days prior to the first dose of study treatment.
- Received prior systemic anticancer therapy including investigational agents within 21 days or, if shorter, within 5 half-lives prior to the first dose of study treatment. Participants must have recovered from all AEs due to previous therapies to Grade ≤1 or baseline. Participants with Grade ≤2 neuropathy may be eligible. Participants with endocrine-related AEs Grade ≤2 requiring treatment or hormone replacement may be eligible.
- Prior autologous or allogeneic hematopoietic stem cell transplant or solid organ transplant.
- Received previous treatment with another agent targeting CD24.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Sequentiële toewijzing
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: PHST001 Monotherapy
Participants will receive PHST001 monotherapy administered once every 3 weeks (Q3W). In Phase 1a, PHST001 will be evaluated in sequential dose-escalation cohorts at planned dose levels of 0.1, 0.3, 1.0, 2.0, 4.0, 6.0, 9.0, 18.0, and 36.0 mg/kg. Dose levels may be modified or additional dose levels evaluated based on emerging safety, pharmacokinetic, pharmacodynamic, and antitumor activity data. Participants in the Phase 1b biomarker cohort may also receive PHST001 monotherapy. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. |
|
Experimenteel: PHST001 + Paclitaxel
Participants will receive PHST001 in combination with paclitaxel. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in tumor-specific expansion cohorts, including participants with ovarian carcinoma, endometrial carcinoma, or cholangiocarcinoma, and/or in the biomarker cohort. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. Paclitaxel used as per standard of care.
Andere namen:
|
|
Experimenteel: PHST001 + Topotecan
Participants will receive PHST001 in combination with topotecan. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in the ovarian carcinoma expansion cohort and/or biomarker cohort. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. Topotecan used as per standard of care.
Andere namen:
|
|
Experimenteel: PHST001 + Doxorubicin
Participants will receive PHST001 in combination with doxorubicin. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in ovarian carcinoma or endometrial carcinoma expansion cohorts and/or the biomarker cohort. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. Doxorubicin used as per standard of care.
Andere namen:
|
|
Experimenteel: PHST001 + FOLFIRI
Participants will receive PHST001 in combination with FOLFIRI (5-fluorouracil, folinic acid, and irinotecan). The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in the cholangiocarcinoma expansion cohort and/or biomarker cohort. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. FOLFIRI used as per standard of care.
Andere namen:
|
|
Experimenteel: PHST001 + FOLFOX
Participants will receive PHST001 in combination with FOLFOX (5-fluorouracil, folinic acid, and oxaliplatin). The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in the cholangiocarcinoma expansion cohort and/or biomarker cohort. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. FOLFOX used as per standard of care.
Andere namen:
|
|
Experimenteel: PHST001 + Gemcitabine
Participants will receive PHST001 in combination with gemcitabine. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in ovarian carcinoma or cholangiocarcinoma expansion cohorts and/or the biomarker cohort. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. Gemcitabine used as per standard of care.
Andere namen:
|
|
Experimenteel: PHST001 + Mirvetuximab Soravtansine
Participants will receive PHST001 in combination with mirvetuximab soravtansine. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in the ovarian carcinoma expansion cohort and/or in the biomarker cohort. Half of the participants in the randomized ovarian carcinoma cohort may be randomly assigned to receive PHST001 in combination with mirvetuximab soravtansine. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. Mirvetuximab soravtansine used as per standard of care.
Andere namen:
|
|
Experimenteel: PHST001 + Trastuzumab Deruxtecan
Participants will receive PHST001 in combination with trastuzumab deruxtecan. The combination will initially be evaluated in a Phase 1b safety run-in group. Following safety clearance, the combination may be evaluated in participants with advanced or metastatic breast cancer and/or in the biomarker cohort. |
PHST001 is an anti-CD24 macrophage checkpoint inhibitor, administered as IV infusions every 3-weeks (Q3W) dosing intervals. Trastuzumab deruxtecan used as per standard of care.
Andere namen:
|
|
Actieve vergelijker: Mirvetuximab Soravtansine Monotherapy
Participants with ovarian carcinoma enrolled in the randomized Phase 1b expansion cohort will be randomized 1:1 to receive mirvetuximab soravtansine monotherapy or mirvetuximab soravtansine in combination with PHST001. Participants assigned to this arm will receive mirvetuximab soravtansine monotherapy. |
Mirvetuximab soravtansine used as per standard of care.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Frequency of Dose-Limiting Toxicities (DLTs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Tijdsspanne: From first dose of PHST001 through 21 days after the first dose of PHST001
|
Based on toxicities observed |
From first dose of PHST001 through 21 days after the first dose of PHST001
|
|
Frequency of Serious Adverse Events (SAEs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Tijdsspanne: From signed consent up to 90 days after the last dose of PHST001
|
Based on toxicities observed |
From signed consent up to 90 days after the last dose of PHST001
|
|
Frequency of Treatment Emergent Adverse Events (TEAEs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Tijdsspanne: From first dose up to 90 days after the last dose of PHST001
|
Based on toxicities observed |
From first dose up to 90 days after the last dose of PHST001
|
|
Frequency of Treatment Related Adverse Events (TRAEs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Tijdsspanne: From first dose up to 90 days after the last dose of PHST001
|
Based on toxicities observed |
From first dose up to 90 days after the last dose of PHST001
|
|
Frequency of Adverse Events of Special Interest (AESIs) to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Tijdsspanne: From first dose up to 90 days after the last dose of PHST001
|
Based on toxicities observed |
From first dose up to 90 days after the last dose of PHST001
|
|
Frequency of AEs Leading to Dose Interruption or Treatment Discontinuation and AEs Leading to Death to assess the safety and tolerability of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Tijdsspanne: From first dose up to 90 days after the last dose of PHST001
|
Based on toxicities observed |
From first dose up to 90 days after the last dose of PHST001
|
|
Overall Response Rate (ORR) based on RECIST v1.1 to assess the preliminary antitumor activity of PHST001 in combination with anticancer therapy (Phase 1b non-randomized cohorts only)
Tijdsspanne: From screening and during treatment up to 2 years
|
Defined as the proportion of subjects with confirmed complete response (CR) or partial response (PR); a confirmed response is a response that persists on repeat-imaging ≥ 4 weeks after initial documentation of response. |
From screening and during treatment up to 2 years
|
|
Progression-Free Survival (PFS) based on RECIST v1.1 to assess the preliminary antitumor activity of PHST001 in combination with anticancer therapy (Phase 1b randomized cohort only)
Tijdsspanne: From screening and during treatment up to 2 years
|
Defined as the time from first dose of PHST001 to first documentation of radiographic disease progression or death, whichever occurs first. |
From screening and during treatment up to 2 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Overall Response Rate (ORR) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b - randomized cohort only)
Tijdsspanne: From screening and during treatment up to 2 years
|
Defined as the proportion of subjects with confirmed complete response (CR) or partial response (PR); a confirmed response is a response that persists on repeat-imaging ≥ 4 weeks after initial documentation of response. |
From screening and during treatment up to 2 years
|
|
Duration of Response (DOR) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b)
Tijdsspanne: From screening and during treatment up to 2 years
|
Defined as time from date of first objective response (either CR or PR) to first documentation of radiographic disease progression. |
From screening and during treatment up to 2 years
|
|
Best Overall Response (BOR) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b)
Tijdsspanne: From screening and during treatment up to 2 years
|
Defined as the best response recorded for a participant across all time-point assessments from the start of treatment until disease progression or end of treatment. |
From screening and during treatment up to 2 years
|
|
Progression-Free Survival (PFS) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b - non-randomized cohorts only) .
Tijdsspanne: From screening and during treatment up to 2 years
|
Defined as the time from first dose of PHST001 to first documentation of radiographic disease progression or death, whichever occurs first. |
From screening and during treatment up to 2 years
|
|
Overall Survival (OS) based on RECIST v1.1 (or RANO for primary CNS Tumors) to assess the preliminary antitumor activity of PHST001 as monotherapy (Phase 1a) and in combination with anticancer therapy (Phase 1b).
Tijdsspanne: From screening and during treatment up to 2 years
|
Defined as the time from first dose of PHST001 to the date of death. |
From screening and during treatment up to 2 years
|
|
Maximum Observed Concentration (Cmax) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b).
Tijdsspanne: From treatment until 90 days after last dose of PHST001
|
Defined as the maximum blood concentration of a dose of PHST001 |
From treatment until 90 days after last dose of PHST001
|
|
Time to Maximum Concentration (tmax) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Tijdsspanne: From treatment until 90 days after last dose of PHST001
|
Defined as the time required for a dose of PHST001 to reach its maximum blood concentration (Cmax) after administration. |
From treatment until 90 days after last dose of PHST001
|
|
Concentration at the End of a Dosing Interval (Ctrough) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Tijdsspanne: From treatment until 90 days after last dose of PHST001
|
Defined as the blood concentration of a dose of PHST001 at the end of the dosing interval (just prior to next drug administration). |
From treatment until 90 days after last dose of PHST001
|
|
Area Under the Concentration-time Curve (AUC) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Tijdsspanne: From treatment until 90 days after last dose of PHST001
|
Defined as the total PHST001 exposure over time, calculated as the integral of the plasma concentration-time profile. |
From treatment until 90 days after last dose of PHST001
|
|
Volume of Distribution at Steady-state (Vss) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Tijdsspanne: From treatment until 90 days after last dose of PHST001
|
Defined as how widely PHST001 spreads throughout the body once things have stabilized after a dose has been administered. |
From treatment until 90 days after last dose of PHST001
|
|
Clearance (CL) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Tijdsspanne: From treatment until 90 days after last dose of PHST001
|
Defined as the rate at which the body "cleans out" a dose of PHST001 from the bloodstream. |
From treatment until 90 days after last dose of PHST001
|
|
Terminal Elimination Half-life (t½) to characterize the serum PK of PHST001 as monotherapy (Phase 1a) or in combination with anticancer therapy (Phase 1b)
Tijdsspanne: From treatment until 90 days after last dose of PHST001
|
Defined as the time it takes for the amount of PHST001 in the body to drop by half during the final phase of elimination. |
From treatment until 90 days after last dose of PHST001
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Genitale ziekten
- Endocriene systeemziekten
- Ziekten van het zenuwstelsel
- Urogenitale neoplasmata
- Neoplasmata per site
- Neoplasmata
- Vrouwelijke urogenitale ziekten
- Vrouwelijke urogenitale ziekten en zwangerschapscomplicaties
- Neoplasmata per histologisch type
- Baarmoeder Ziekten
- Genitale ziekten, vrouw
- Endocriene klierneoplasmata
- Neoplasmata, glandulair en epitheel
- Adenocarcinoom
- Ovariële ziekten
- Adnexale ziekten
- Genitale neoplasmata, vrouwelijk
- Gonadale aandoeningen
- Huidziektes
- Borst ziekten
- Carcinoom
- Neoplasmata van het zenuwstelsel
- Baarmoeder Neoplasmata
- Sarcoom
- Neoplasmata, bindweefsel en zacht weefsel
- Neoplasmata, complex en gemengd
- Ziekten van de eileiders
- Huid- en bindweefselaandoeningen
- Ovariumneoplasmata
- Borstneoplasmata
- Cholangiocarcinoom
- Endometriumneoplasmata
- Carcinosarcoom
- Neoplasmata van het centrale zenuwstelsel
- Eileiderneoplasmata
- Organische chemicaliën
- Heterocyclische verbindingen, 1-ring
- Heterocyclische verbindingen
- Heterocyclische verbindingen, 2-ring
- Heterocyclische verbindingen, gefuseerd ring
- Koolwaterstoffen
- Cycloparaffins
- Koolwaterstoffen, alicyclisch
- Koolwaterstoffen, cyclisch
- Terpenen
- Koolhydraten
- Camptothecin
- Alkaloïden
- Polycyclische aromatische koolwaterstoffen
- Koolwaterstoffen, aromatisch
- Polycyclische verbindingen
- Glycosiden
- Enzymen en co -enzymen
- Taxoids
- Cyclodecanes
- Diterpenen
- Deoxycytidine
- Cytidine
- Pyrimidine -nucleosiden
- Pyrimidines
- Formyltetrahydrofolates
- Tetrahydrofolaten
- Foliumzuur
- Pterins
- Pteridines
- Uracil
- Pyrimidinonen
- Antracyclines
- Naftacenes
- Aminoglycosides
- Co -enzymen
- Daunorubicine
- Gemcitabine
- Fluorouracil
- Leucovorin
- Doxorubicine
- Paclitaxel
- Topotecan
- mirvetuximab soravtansine
- trastuzumab deruxtecan
- FOLFOX -protocol
- IFL -protocol
Andere studie-ID-nummers
- PHST001-101
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .